On the day after President Biden announced that every American will be eligible for a COVID-19 vaccine by May 1, two top Rice University scientists focused on the pandemic voiced both optimism and grave concern.
In one of the first studies of its kind, an analysis of camera-trap data from 15 wildlife preserves in tropical rainforests revealed a previously unknown relationship between the biodiversity of mammals and the forests in which they live.
Researchers receive funding for up to $1 million to develop a real-time electronic sensor able to detect minute amounts of the airborne virus that causes COVID-19 infection.
An algorithm by Rice University scientists predicts the structures and melting temperatures of collagen, the triple helix that accounts for about a third of the body’s proteins and forms the fibrous glue in skin, bones, muscles, tendons and ligaments.
Rice bioengineers harness the CRISPR/Cas9 system to program histones, the support proteins that wrap up and control human DNA, to manipulate gene activation and phosphorylation. The new technology enables innovative ways to find and manipulate genes and pathways responsible for diseases.
Researchers detail the mechanism that allows propofol, a common anesthetic, to halt the movement of kinesin proteins that deliver cargoes to the far reaches of cells.
Researchers from Rice University and Baylor College of Medicine have shown that colored light can both activate and deactivate genes of gut bacteria in the intestines of worms. The research shows how optogenetic technology can be used to investigate the health impacts of gut bacteria.
Rice University biochemists have discovered membrane-divided subcompartments within organelles called peroxisomes, essential pieces of metabolic machinery for all higher order life from yeast to humans. The research appears this week in Nature Communications.
Atom-scale models of proteins that incorporate ligands, like drug molecules, show a strong correlation between minimally frustrated binding sites and drug specificity. Such models could lead to better-designed drugs with fewer side effects.
Rice University biochemists have proposed that degenerative diseases as varied as Alzheimer's, Parkinson's and muscle atrophy occur in two distinct phases marked by protein signaling changes that could result in patients responding differently to the same treatment.